Large cell neuroendocrine lung carcinoma: consensus statement from The British Thoracic Oncology Group and the Association of Pulmonary Pathologists.
Colin R LindsayEmily C ShawDavid A MooreDoris RasslMariam Jamal-HanjaniNicola SteeleSalma NaheedCraig DickFiona TaylorHelen AdderleyFiona BlackYvonne SummersMatt EvansAlexandra RiceAurelie FabreWilliam A WallaceSiobhan NicholsonAlex HaraganPhillipe TaniereAndrew G NicholsonGavin LaingJudith CaveMartin D ForsterFiona BlackhallJohn GosneySanjay PopatKeith M KerrPublished in: British journal of cancer (2021)
Over the past 10 years, lung cancer clinical and translational research has been characterised by exponential progress, exemplified by the introduction of molecularly targeted therapies, immunotherapy and chemo-immunotherapy combinations to stage III and IV non-small cell lung cancer. Along with squamous and small cell lung cancers, large cell neuroendocrine carcinoma (LCNEC) now represents an area of unmet need, particularly hampered by the lack of an encompassing pathological definition that can facilitate real-world and clinical trial progress. The steps we have proposed in this article represent an iterative and rational path forward towards clinical breakthroughs that can be modelled on success in other lung cancer pathologies.
Keyphrases
- single cell
- clinical trial
- cell therapy
- randomized controlled trial
- palliative care
- photodynamic therapy
- spinal cord
- stem cells
- squamous cell carcinoma
- magnetic resonance
- radiation therapy
- mesenchymal stem cells
- cancer therapy
- study protocol
- drug delivery
- computed tomography
- low grade
- high grade
- spinal cord injury
- phase ii
- combination therapy
- bone marrow
- locally advanced
- phase iii
- dual energy